Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy

Area of Science:

• Oncology
• Cancer Metabolism
• Immunotherapy

Background:

• Drug resistance is a major challenge in cancer therapy.
• Cancer cells adapt metabolism (e.g., oxidative phosphorylation, glutamine reliance) to survive and evade immune responses.
• Metabolic reprogramming contributes to immune evasion via ROS generation and PD-L1 upregulation.

Purpose of the Study:

• To review targeting metabolic vulnerabilities in drug-resistant cancers.
• To explore combining metabolic inhibitors with immune checkpoint inhibitors (ICIs).
• To discuss overcoming metabolic and immune evasion mechanisms in cancer.

Main Methods:

• Review of key metabolic pathways in drug resistance (glycolysis, glutamine metabolism, kynurenine pathway).
• Analysis of combining metabolic inhibitors with immune checkpoint inhibitors (ICIs), specifically anti-PD-1/PD-L1 therapies.
• Examination of early clinical trial data for combined metabolic and immune therapies.

Main Results:

• Metabolic adaptations are crucial for cancer cell survival and immune evasion.
• Combined metabolic and immune therapies show early promise in clinical trials.
• Further research is needed to optimize treatment combinations and identify patient biomarkers.

Conclusions:

• Targeting cancer metabolism alongside immune checkpoint blockade presents a novel therapeutic strategy.
• This combined approach may overcome drug resistance and immune evasion, improving patient outcomes.
• Future directions include personalized treatments based on tumor metabolic profiles and broader application across tumor types.